Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:FEMY

Femasys 8/8/2025 Earnings Report

Femasys logo
$0.36 +0.01 (+1.74%)
Closing price 04:00 PM Eastern
Extended Trading
$0.36 +0.00 (+0.61%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Femasys EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.41 million
Expected Revenue
$0.80 million
Beat/Miss
Missed by -$390.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Date
8/8/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Femasys Earnings Headlines

Femasys updates corporate presentation on women’s health portfolio
May 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/femasys-updates-corporate-presentation-on-womens-health-portfolio?utm_source=marketbeat.com&utm_medium=referral
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294028/0/en/femasys-expands-fertility-care-portfolio-in-europe-with-ce-mark-approval-for-femhsg-catheter.html
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel
May 18 at 1:00 AM  |  Behind the Markets (Ad)
Femasys Inc.: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
May 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68446325-femasys-inc-femasys-announces-financial-results-for-quarter-ended-march-31-2026-and-provides-corporate-update-399.htm
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
May 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/08/3291326/0/en/femasys-announces-financial-results-for-quarter-ended-march-31-2026-and-provides-corporate-update.html
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287801/0/en/femasys-enables-ob-gyns-to-deliver-first-line-fertility-treatment-with-initial-commercial-use-of-femaseed-complete.html
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY) International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools.

Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.

View Femasys Profile
Earnings Tools